{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:12Z","timestamp":1759451952297,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.humimm.2025.111306","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:43:35Z","timestamp":1744735415000},"page":"111306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First report on PARK-2 gene polymorphism and its relation to clinical pathological parameters and gene expression in Non-Hodgkin lymphoma"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-1160","authenticated-orcid":false,"given":"Gehan Abd-Elfatah","family":"Tawfeek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham Ahmed","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.humimm.2025.111306_b0005","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clml.2020.05.010","article-title":"Influence of Rurality, Race, and Ethnicity on Non-Hodgkin Lymphoma Incidence","volume":"20","author":"Blansky","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"13","key":"10.1016\/j.humimm.2025.111306_b0010","article-title":"The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends","volume":"2","author":"Chu","year":"2023","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.humimm.2025.111306_b0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and Etiology of Leukemia and Lymphoma","volume":"10","author":"Bispo","year":"2020","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.humimm.2025.111306_b0020","doi-asserted-by":"crossref","unstructured":"Yanik EL, Smith JM, Shiels MS, Clarke CA, Lynch CF, Kahn AR, Koch L, Pawlish KS, Engels EA.Cancer risk after pediatric solid organ transplantation.Pediatrics2017;139: e20163893 10.1542\/peds.2016-3893.","DOI":"10.1542\/peds.2016-3893"},{"key":"10.1016\/j.humimm.2025.111306_b0025","doi-asserted-by":"crossref","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. Med Sci (Basel). 2021 30;9(1):5.","DOI":"10.3390\/medsci9010005"},{"key":"10.1016\/j.humimm.2025.111306_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.critrevonc.2018.05.018","article-title":"Anthropometric factors and non-Hodgkin's lymphoma risk: Systematic review and meta-analysis of prospective studies","volume":"129","author":"Hidayat","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.humimm.2025.111306_b0035","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/oemed-2018-105154","article-title":"Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma","volume":"75","author":"De Roos","year":"2018","journal-title":"Occup Environ Med"},{"issue":"15","key":"10.1016\/j.humimm.2025.111306_b0040","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.humimm.2025.111306_b0045","first-page":"355","article-title":"Methylenetetrahydrofolate reductase gene polymorphisms (677C > T and 1298A > C) in Egyptian patients with non-hodgkin lymphoma","volume":"8","author":"Nasr","year":"2012","journal-title":"RGCC International GmbH"},{"key":"10.1016\/j.humimm.2025.111306_b0050","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence","author":"Ollila","year":"2018","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.humimm.2025.111306_b0055","article-title":"A Novel Mutation ofPARK-2Gene in a Patient with Early-onset Parkinson's Disease","volume":"30;35(3):e140","author":"Alafifi","year":"2020","journal-title":"Oman Med J."},{"issue":"1","key":"10.1016\/j.humimm.2025.111306_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(02)00337-4","article-title":"Part I: parkin-associated proteins and Parkinson's disease","volume":"45","author":"Dev","year":"2003","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.humimm.2025.111306_b0065","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/ncomms2982","article-title":"Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases","volume":"4","author":"Riley","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.humimm.2025.111306_b0070","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8260652","article-title":"The Progress of Methylation Regulation in Gene Expression of Cervical Cancer","volume":"2018","author":"Feng","year":"2018","journal-title":"Int J Genomics."},{"issue":"1","key":"10.1016\/j.humimm.2025.111306_b0075","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1186\/s12885-019-6013-6","article-title":"Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients","volume":"19","author":"Wahabi","year":"2019","journal-title":"BMC Cancer."},{"issue":"3","key":"10.1016\/j.humimm.2025.111306_b0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5152\/tjg.2020.18823","article-title":"Implication of alterations in Parkin gene among North Indian patients with colorectal cancer","volume":"31","author":"Tiwari","year":"2020","journal-title":"Turk J Gastroenterol."},{"issue":"6","key":"10.1016\/j.humimm.2025.111306_b0085","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/ng.2981","article-title":"Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1\/S cyclins","volume":"46","author":"Gong","year":"2014","journal-title":"Nat Genet."},{"issue":"9","key":"10.1016\/j.humimm.2025.111306_b0090","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fonc.2019.00790","article-title":"PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer","volume":"23","author":"Duan","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.humimm.2025.111306_b0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41401-019-0260-6","article-title":"Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1\/Parkin-mediated mitophagy in lung cancer cells","volume":"41","author":"Zhang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.humimm.2025.111306_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.humimm.2025.111306_b0105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12029-021-00693-z","article-title":"Association of PARK-2 Non-synonyms Polymorphisms and Their In Silico Validation Among North Indian Colorectal Cancer Patients","volume":"53","author":"Bhat","year":"2022","journal-title":"J Gastrointest Cancer."},{"key":"10.1016\/j.humimm.2025.111306_b0110","article-title":"Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients","volume":"20;19(1):820","author":"Wahabi","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.humimm.2025.111306_b0115","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317703635","article-title":"Genetic and epigenetic alterations affecting PARK-2 expression in cervical neoplasm among North Indian patients","volume":"39","author":"Naseem","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.humimm.2025.111306_b0120","article-title":"DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities","volume":"24;23(23):14672","author":"Jurkovicova","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.humimm.2025.111306_b0125","article-title":"Genomic landscape of mature B-cell non-Hodgkin lymphomas - an appraisal from lymphomagenesis to drug resistance","volume":"12;34(1):52","author":"Panda","year":"2022","journal-title":"J Egypt Natl Canc Inst."},{"key":"10.1016\/j.humimm.2025.111306_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1056030","article-title":"Age-period-cohort analysis of gender differential trends in incidence and mortality of non-Hodgkin lymphoma in China, 1990-2019","volume":"12","author":"Yao","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.humimm.2025.111306_b0135","article-title":"Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy","volume":"29;5(4):e0038","author":"Horesh","year":"2014","journal-title":"Rambam Maimonides Med J."},{"key":"10.1016\/j.humimm.2025.111306_b0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00042737-200402000-00003","article-title":"The prevalence of hepatitis C virus infection in patients with non-Hodgkin\u2019s lymphoma","volume":"16","author":"Gisbert","year":"2004","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"1","key":"10.1016\/j.humimm.2025.111306_b0145","first-page":"17","article-title":"Efficacy of ribavirin to prevent hepatitis reactivation in hepatitis C virus-infected patients treated for non-Hodgkin lymphoma","volume":"3","author":"Abu-Taleb","year":"2013","journal-title":"Afro-Egypt J Infect Endem Dis."},{"key":"10.1016\/j.humimm.2025.111306_b0150","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/emboj.2013.125","article-title":"Structure of the human Parkin ligase domain in an autoinhibited state","volume":"32","author":"Wauer","year":"2013","journal-title":"EMBO J"},{"key":"10.1016\/j.humimm.2025.111306_b0155","article-title":"Post-translational modification of Parkin and its research progress in cancer","volume":"21;39(1):77","author":"Ding","year":"2019","journal-title":"Cancer Commun (lond)"},{"key":"10.1016\/j.humimm.2025.111306_b0160","article-title":"PINK1\/Parkin Influences Cell Cycle by Sequestering TBK1 at Damaged Mitochondria, Inhibiting Mitosis","volume":"1 ;29(1):225\u2013235.e5","author":"Sarraf","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.humimm.2025.111306_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101767","article-title":"The PINK1\/PARK2\/optineurin pathway of mitophagy is activated for protection in septic acute kidney injury","volume":"38","author":"Wang","year":"2021","journal-title":"Redox Biol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885925000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885925000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:18:23Z","timestamp":1759400303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885925000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0198885925000771"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2025.111306","relation":{},"ISSN":["0198-8859"],"issn-type":[{"type":"print","value":"0198-8859"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First report on PARK-2 gene polymorphism and its relation to clinical pathological parameters and gene expression in Non-Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2025.111306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111306"}}